Reversion From Chronic to Episodic Migraine and Effects on Patient-reported Outcomes Following Treatment With Erenumab: Post-hoc Analysis of the Randomised, 12-week, Double-blind DRAGON Study

被引：0

作者：

Wang, Shuu-Jiun ^{[1
]}

Kim, Byung-Kun ^{[2
]}

Wang, Hebo ^{[3
]}

Zhou, Jiying ^{[4
]}

Wan, Qi ^{[5
]}

Yu, Tingmin ^{[6
]}

Lian, Yajun ^{[7
]}

Arkuszewski, Michal ^{[8
]}

Ecochard, Laurent ^{[8
]}

Wen, Shihua ^{[9
]}

Yin, Fangfang ^{[10
]}

Li, Zheng ^{[10
]}

Su, Wendy ^{[9
]}

Yu, Shengyuan ^{[11
]}

机构：

[1] Taipei Vet Gen Hosp, Neurol Inst, Taipei, Taiwan

[2] Eulji Univ, Nowon Eulji Med Ctr, Sch Med, Seoul, South Korea

[3] Hebei Gen Hosp, Shijiazhuang, Peoples R China

[4] Chongqing Med Univ, Affiliated Hosp 1, Chongqing, Peoples R China

[5] Jiangsu Prov Hosp, Nanjing, Peoples R China

[6] Second Hosp Jilin Univ, Changchun, Peoples R China

[7] Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou, Peoples R China

[8] Novartis Pharma AG, Basel, Switzerland

[9] Novartis Pharmaceutical Corp, E Hanover, NJ USA

[10] China Novartis Inst Biomed Res Co Ltd, Shanghai, Peoples R China

[11] Chinese Peoples Liberat Army Gen Hosp, Beijing, Peoples R China

来源：

CEPHALALGIA | 2022年 / 42卷 / 1_SUPPL期

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

MTIS22-EP-

引用

页码：29 / 31

页数：3

共 50 条

[1] Reversion from chronic migraine to episodic migraine following treatment with erenumab: Results of a post-hoc analysis of a randomized, 12-week, double-blind study and a 52-week, open-label extension
Lipton, Richard B.
Tepper, Stewart J.
Silberstein, Stephen D.
Kudrow, David
Ashina, Messoud
Reuter, Uwe
Dodick, David W.
Zhang, Feng
Rippon, Gregory A.
Cheng, Sunfa
Mikol, Daniel D.
CEPHALALGIA, 2021, 41 (01) : 6 - 16
[2] Erenumab in chronic migraine Patient-reported outcomes in a randomized double-blind study
Lipton, Richard B.
Tepper, Stewart J.
Reuter, Uwe
Silberstein, Stephen
Stewart, Walter F.
Nilsen, Jon
Leonardi, Dean K.
Desai, Pooja
Cheng, Sunfa
Mikol, Daniel D.
Lenz, Robert
NEUROLOGY, 2019, 92 (19) : E2250 - E2260
[3] Effect of erenumab on the reversion from chronic migraine to episodic migraine in an Asian population: A post hoc analysis of the DRAGON study
Wang, Shuu-Jiun
Kim, Byung-Kun
Wang, Hebo
Zhou, Jiying
Wan, Qi
Yu, Tingmin
Lian, Yajun
Arkuszewski, Michal
Ecochard, Laurent
Snellman, Josefin
Wen, Shihua
Yin, Fangfang
Li, Zheng
Su, Wendy
Yu, Shengyuan
HEADACHE, 2025, 65 (01): : 143 - 152
[4] Effect of Erenumab on Patient-Reported Outcomes in Episodic Migraine Patients with Prior Prophylactic Treatment Failure: Results from a Post-Hoc Analysis of the STRIVE study
Pascual, J.
Buse, D.
Starling, A. J.
Ailani, J.
Zhang, F.
Wen, S.
Bilitou, A.
Desai, P.
Picard, H.
Klatt, J.
Mikol, D.
EUROPEAN JOURNAL OF NEUROLOGY, 2018, 25 : 409 - 409
[5] Effect of Erenumab on Patient-Reported Outcomes in Episodic Migraine Patients with Prior Prophylactic Treatment Failure: Results from a Post-Hoc Analysis of the STRIVE Study
Pascual, J.
Buse, D. C.
Starling, A. J.
Ailani, J.
Zhang, F.
Wen, S.
Bilitou, A.
Desai, P.
Pichard, H.
Klatt, J.
Mikol, D.
HEADACHE, 2018, 58 : 179 - 180
[6] Patient-Reported Outcomes from the ARISE Trial: A Phase 3, Randomized, Double-Blind Study of Erenumab in Subjects with Episodic Migraine
Ashina, M.
Brandes, J. L.
Katsarava, Z.
Lipton, R. B.
Pascual, J.
Palmer, K.
Desai, P.
Picard, H.
Mikol, D. D.
Lenz, R. A.
HEADACHE, 2017, 57 : 192 - 192
[7] Patient-Reported Outcomes from the STRIVE Trial: A Phase 3, Randomized, Double-Blind Study of Erenumab in Subjects with Episodic Migraine
Buse, D. C.
Lipton, R. B.
Hallstrom, Y.
Reuter, U.
Tepper, S. J.
Zhang, F.
Sapra, S.
Picard, H.
Mikol, D. D.
Lenz, R. A.
HEADACHE, 2017, 57 : 198 - 199
[8] Patient-reported outcomes in patients with chronic migraine receiving placebo or erenumab (AMG 334) in a phase 2, randomised, double-blind study
Lipton, Richard B.
Tepper, Stewart J.
Reuter, Uwe
Silberstein, Stephen
Stewart, Walter
Leonardi, Dean
Desai, Pooja
Cheng, Sunfa
Mikol, Daniel D.
Lenz, Robert A.
JOURNAL OF HEADACHE AND PAIN, 2017, 18
[9] EFFECT OF ERENUMAB ON PATIENT-REPORTED OUTCOMES IN EPISODIC MIGRAINE PATIENTS WITH PRIOR PROPHYLACTIC TREATMENT FAILURE: RESULTS FROM A POST HOC ANALYSIS OF THE STRIVE STUDY
Pascual, J.
Buse, D. C.
Starling, A.
Ailani, J.
Zhang, F.
Wen, S.
Bilitou, A.
Desai, P.
Picard, H.
Klatt, J.
Mikol, D. D.
CEPHALALGIA, 2018, 38 : 47 - 48
[10] Patient-Reported Outcomes in Patients with Chronic Migraine Receiving Placebo or Erenumab (AMG 334) in a Phase 2, Randomized, Double-Blind Study
Tepper, Stewart
Lipton, Richard
Reuter, Uwe
Silberstein, Stephen
Stewart, Walter
Leonardi, Dean
Desai, Pooja
Cheng, Sunfa
Mikol, Dan
Lenz, Robert
NEUROLOGY, 2017, 88

← 1 2 3 4 5 →